Title (en)

NEW HISTONE DEACETYLASES INHIBITORS

Title (de)

NEUE HISTONDEACETYLASEINHIBITOREN

Title (fr)

NOUVEAUX INHIBITEURS DES HISTONE-DEACETYLASES

Publication

EP 1814850 A1 20070808 (EN)

Application

EP 05797249 A 20050930

Priority

- EP 2005054949 W 20050930
- IT MI20041869 A 20041001

Abstract (en)

[origin: WO2006037761A1] New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R₁ is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R₃ is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.

IPC 8 full level

C07D 207/32 (2006.01); **A61K 31/165** (2006.01); **A61K 31/435** (2006.01); **A61K 31/4436** (2006.01); **A61P 35/00** (2006.01); **C07C 259/06** (2006.01); **C07D 213/46** (2006.01); **C07D 307/46** (2006.01); **C07D 307/80** (2006.01); **C07D 333/22** (2006.01); **C07D 333/56** (2006.01); **C07D 409/06** (2006.01)

CPC (source: EP KR US)

A61K 31/165 (2013.01 - KR); **A61P 1/04** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 33/00** (2017.12 - EP); **A61P 33/02** (2017.12 - EP); **A61P 33/06** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 39/02** (2017.12 - EP); **A61P 39/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07C 259/06** (2013.01 - EP KR US); **C07D 207/333** (2013.01 - EP US); **C07D 213/46** (2013.01 - EP KR US); **C07D 213/54** (2013.01 - EP US); **C07D 295/112** (2013.01 - EP US); **C07D 307/46** (2013.01 - EP KR US); **C07D 307/80** (2013.01 - EP US); **C07D 333/22** (2013.01 - EP US); **C07D 333/56** (2013.01 - EP US); **C07D 409/06** (2013.01 - EP US)

Citation (search report)

See references of WO 2006037761A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2006037761 A1 20060413; AU 2005291297 A1 20060413; AU 2005291297 B2 20101223; CA 2581730 A1 20060413; CA 2581730 C 20121030; CN 101039905 A 20070919; CN 101039905 B 20120208; EP 1814850 A1 20070808; EP 1814850 B1 20130703; EP 1814850 B9 20150225; ES 2428539 T3 20131108; ES 2428539 T9 20150915; HK 1110579 A1 20080718; IL 182237 A0 20070920; IL 182237 A 20120329; IT MI20041869 A1 20050101; JP 2008514682 A 20080508; JP 4979583 B2 20120718; KR 101191558 B1 20121015; KR 20070070179 A 20070703; MX 2007003641 A 20070814; NZ 554640 A 20090925; PL 1814850 T3 20131231; RU 2007116098 A 20081110; RU 2416599 C2 20110420; US 2008096889 A1 20080424; US 2010240660 A1 20100923; US 7803800 B2 20100928; US 8058273 B2 20111115; ZA 200703390 B 20081029

DOCDB simple family (application)

EP 2005054949 W 20050930; AU 2005291297 A 20050930; CA 2581730 A 20050930; CN 200580035432 A 20050930; EP 05797249 A 20050930; ES 05797249 T 20050930; HK 08101191 A 20080131; IL 18223707 A 20070327; IT MI20041869 A 20041001; JP 2007534030 A 20050930; KR 20077008870 A 20050930; MX 2007003641 A 20050930; NZ 55464005 A 20050930; PL 05797249 T 20050930; RU 2007116098 A 20050930; US 66418705 A 20050930; US 79146510 A 20100601; ZA 200703390 A 20070425